Stephen J. Farr, PhD currently serves as President, Chief Operating Officer and a member of the board of directors of Zogenix, Inc, a company he co-founded in 2006. He has been actively involved in the private and public financing of Zogenix, raising in excess of $250 million, and leading the company through an IPO in November 2010. He is responsible for Research and Development, Clinical Development, Regulatory Affairs, Quality and Manufacturing Development functions. In this role he has overseen the development and NDA approval of Sumavel DosePro, a first-of-its-kind needle-free delivery system for subcutaneous sumatriptan, the Phase 2/3 development of Zohydro, an extended release oral formulation of single-entity hydrocodone, and in developing the early stage pipeline of products based upon the DosePro technology. From 1995 to August 2006, Dr. Farr held positions of increasing responsibility within pharmaceutical sciences and research and development at Aradigm Corporation, and he served most recently as Senior Vice President and Chief Scientific Officer. For 7 years, he led the inhaled insulin collaboration with Novo Nordisk and took the product from laboratory proof-of concept to international Phase 3 clinical studies in Type 1 and Type 2 diabetes. In 2003, he played a key role in identifying and acquiring the DosePro technology and became technical director and executive sponsor for the development of sumatriptan DosePro at Aradigm Corporation. From 1986 to 1994, Dr. Farr was a tenured professor at the Welsh School of Pharmacy, Cardiff University, United Kingdom, concentrating in the areas of physical pharmacy and biopharmaceutics. He has widely published on advanced drug delivery and was made a Fellow of the American Association of Pharmaceutical Scientists in 1998. He is an Adjunct Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University and also serves on the board of ICVRx, Inc., a start-up, clinical stage company focused on new treatments for the treatment of medically refractory epilepsy. Dr. Farr is a Member of the Royal Pharmaceutical Society (registered pharmacist in the United Kingdom) and obtained his Ph.D. degree in Pharmaceutics from the University of Wales.